A recent clinical trial has shown that the weight-loss medication exenatide, similar to Ozempic and Wegovy, does not provide any therapeutic benefit for individuals with Parkinson's disease. Despite earlier studies indicating promising results, the trial found no significant improvements in symptoms or disease progression for patients taking exenatide compared to a placebo group.
A new trial has found that patients with Parkinson's disease do not experience any benefits from taking a weight-loss injection, despite promising early results. The medication, exenatide, is in the same class of drugs as Ozempic and Wegovy. Research ers at University College London conducted the trial, which involved nearly 200 patients in Britain over 96 weeks. Patients were either given weekly exenatide injections or a placebo.
At the end of the study, there were no significant differences in symptom improvement or disease progression between the two groups. Patients taking exenatide experienced minimal weight loss, only an average of 4 pounds (1.8 kg), which was slightly more than the placebo group. This is a disappointing outcome for patients and researchers who had hoped that exenatide could offer a breakthrough treatment for Parkinson's disease. Previous trials in 2008 and 2017 suggested that exenatide could significantly delay the progression and even improve symptoms of Parkinson's, such as tremors and mobility problems
PARKINSON's DISEASE WEIGHT-LOSS MEDICATION EXENATIDE CLINICAL TRIAL HEALTH RESEARCH TREATMENT
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pharmacists issue weight-loss jab warning as online sellers set patient targetsFears have risen over the short time taken to carry out questionnaires to access weight-loss jabs
Read more »
This 'illegal' weight loss jab sold on TikTok could send you to hospitalOfficial data shows that since 2019, this medication has been linked to 23 deaths and 1,179 serious adverse reactions in the UK
Read more »
Mounjaro: Weight-Loss Jab Makes NHS Debut but Millions Still Miss OutMounjaro, a weight-loss injection, is being introduced on the NHS in England to tackle rising obesity rates. While its approval is a significant step, only a fraction of eligible patients will receive access initially due to budget constraints. The decision has sparked debate about the equitable distribution of this potentially life-changing medication.
Read more »
Morrisons launches online clinic for weight loss, hair loss and menopause medsThe service is a partnership between the supermarket and online prescription delivery service Phlo, and allows you to get the medication you need from a clinician without needing to leave the house
Read more »
The Microdosing Temptation: Can a Weekly Jab Keep the Weight Off?A woman reflects on the challenges of maintaining her weight loss after coming off the drug Mounjaro, considering the temptation of holiday treats and the rising trend of microdosing with weight-loss medications.
Read more »
Parents open to child weight support through adult weight management programsParents attending an adult weight management programme, who were worried about their child's weight, would accept support and signposting to services for their child if it was offered, new research led by the University of Bristol has found.
Read more »